Global Ciprofloxacin Ophthalmic Solution Market, By Type (Branded, Generic), Dosage (1-2 Drops/2Hrs., 2 Drops/15 minutes, 2 Drops/30 minutes), Application (Corneal Ulcers, Bacterial Conjunctivitis), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Ciprofloxacin Ophthalmic Solution Market Analysis and Size
Ciprofloxacin ophthalmic solution is generally used once every 15 minutes to 4 hours for 7 to 14 days or more than that. As the incidence of bacterial conjunctivitis founded to be growing worldwide and has been reported to affect more than 2 percent of the population moreover in India the incidence rate reported to be 68.1 percent, this increasing number of affected population enhances the demand of ciprofloxacin ophthalmic solution and thus expected to provide market with the significant growth.
Data Bridge Market Research analyzes that the global ciprofloxacin ophthalmic solution market which was USD 152.24 million in 2022, would rocket up to USD 231.87 million by 2030, and is expected to undergo a CAGR of 5.4% during the forecast period. “Branded” is expected to dominate the type segment of the ciprofloxacin ophthalmic solution market due to the rising number of end user industries, especially in developing economies. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
Report Metric |
Details |
Forecast Period |
2023 to 2030 |
Base Year |
2022 |
Historic Years |
2021 (Customizable to 2015-2020) |
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
Segments Covered |
Type (Branded, Generic), Dosage (1-2 Drops/2Hrs., 2 Drops/15 minutes, 2 Drops/30 minutes), Application (Corneal Ulcers, Bacterial Conjunctivitis), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
Countries Covered |
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America |
Market Players Covered |
Akorn Operating Company LLC (U.S.), Novartis AG (Switzerland), Wellona Pharma (India), Beye, LLC. (U.S.), Symwell Pharmaceuticals (India), SAINTROY LIFESCIENCE (India), Zoister Healthcare Pvt Ltd (India), Cirondrugs (U.S.), Zuche Pharmaceuticals (India), Henry Schein, Inc (U.S.), Systochem Laboratories Ltd. (India), Sentiss Pharma Pvt. Ltd. (India), Amanta Healthcare (India), Focus Labs (India) |
Market Opportunities |
|
Market Definition
Ciprofloxacin ophthalmic solution is a type of fluoroquinolone antibacterial used to treat bacterial infections, reported to affect several eye parts. This solution is indicated for the treatment of infection of the membrane which covers the outside of the eye ball and inside of the eyelids, infection of cornea. This solution can also be used for the treatment of conjunctivitis and it shows effective results by killing the bacterial pathogens targeting eyes.
Global Ciprofloxacin Ophthalmic Solution Market Dynamics
Drivers
- Prevalence of bacterial conjunctivitis
In the U.S., bacterial conjunctivitis is more incident in children than in adults; around 23% of cases are reported in children between the age group of 0-2 years, 28% in children aged 3-9 years, and 13% in children aged 10-19 years. Thus, it acts as a major driver in the market growth.
- Increase in the number of research and development activities
The market growth is boosted by the rise in the number of R&D activities. This will provide beneficial opportunities for the ciprofloxacin ophthalmic solution market. To reassure researchers and pharmaceutical companies to develop advanced medicines, the government is funding research and development (R&D) initiatives.
Opportunity
- Increasing demand for retail pharmacies
The rise in the number of advances in ciprofloxacin ophthalmic solution delivered through retail pharmacies and the increase in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition, patients choose retail pharmacies for purchasing drugs, as these are easily available.
Restraint/Challenge
- Lack of skilled professionals
Skilled ophthalmologists and healthcare professionals are essential for the proper diagnosis and prescription of ciprofloxacin ophthalmic solutions. Without an adequate number of skilled professionals, patients may not receive the appropriate treatment, leading to underutilization of the product.
This ciprofloxacin ophthalmic solution market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the ciprofloxacin ophthalmic solution market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2023, the New York Times reported that the Centers for Disease Control and Prevention (CDC) has traced multiple cases of blindness and death due to eye drops imported from India. The agency also states its rising worry over the infection gaining a foothold in the US region. The bacteria causing the infection is highly drug-resistant and the region’s Food and Drug Administration (FDA) has already stopped the import of the eye drops
- In March 2023, the US FDA recalled three brands of eye drops since they have been linked to vision loss, serious infections, and death. The three brands under scrutiny are Purely Soothing 15% MSM Drops, Artificial Tears Lubricant Eye Drops distributed by EzriCare, LLC and DELSAM Pharma, and Brimonidine Tartrate Ophthalmic Solution, 0.15%
Global Ciprofloxacin Ophthalmic Solution Market Scope
The ciprofloxacin ophthalmic solution market is segmented on the basis of type, dosage, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Branded
- Generic
Dosage
- 1-2 Drops/2Hrs.
- 2 Drops/15 minutes
- 2 Drops/30 minutes
Application
- Corneal Ulcers
- Bacterial Conjunctivitis
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Ciprofloxacin Ophthalmic Solution Market Regional Analysis/Insights
The ciprofloxacin ophthalmic solution market is analyzed and market size insights and trends are provided by country, type, dosage, application, end user, and distribution channel as referenced above.
The countries covered in the ciprofloxacin ophthalmic solution market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
North America is expected to dominate the market due to the presence of advanced healthcare infrastructure.
Asia-Pacific is expected to grow during the forecast period due to surge in regional investments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The ciprofloxacin ophthalmic solution market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the ciprofloxacin ophthalmic solution market , the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Ciprofloxacin ophthalmic solution market.
Competitive Landscape and Ciprofloxacin Ophthalmic Solution Market Share Analysis
The ciprofloxacin ophthalmic solution market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Ciprofloxacin ophthalmic solution market.
Some of the major players operating in the ciprofloxacin ophthalmic solution market are:
- Akorn Operating Company LLC (U.S.)
- Novartis AG (Switzerland)
- Wellona Pharma (India)
- Beye, LLC. (U.S.)
- Symwell Pharmaceuticals (India)
- SAINTROY LIFESCIENCE (India)
- Zoister Healthcare Pvt Ltd (India)
- Cirondrugs (U.S.)
- Zuche Pharmaceuticals (India)
- Henry Schein, Inc (U.S.)
- Systochem Laboratories Ltd. (India)
- Sentiss Pharma Pvt. Ltd. (India)
- Amanta Healthcare (India)
- Focus Labs (India)
SKU-